Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received a second round of funding from the Bill & Melinda Gates Foundation to accelerate global adoption of AI algorithms on Philips Lumify Handheld Ultrasound. By using AI to simplify key measurements to identify abnormalities during

The Royal Wolverhampton NHS Trust (RWT) has just signed a 10-year contract with System C for an integrated electronic patient record (EPR) system, which will replace the trust's in-house built EPR and accelerate its digital maturity and roadmap.

RWT, which is one of the largest acute and community providers in the West Midlands, will be taking a two-step approach to the roll out.

World leading AI pioneer, Orbital Global, is proud to announce that it is a member of a new Horizon Europe research and innovation consortium, which aims to personalise prevention and treatment of cardiovascular diseases. Led by Novo Nordisk and Maastricht University, the iCARE4CVD (individualised care from early risk of cardiovascular disease to established heart failure) consortium is formed of thirty-three leading international partners from civil society, academia, and industry.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced the launch of Visual Patient Avatar, a revolutionary new monitoring solution that translates critical, yet complex patient data into a straightforward visual design as an easy-to-understand avatar display.

Siemens Healthineers and Braunschweig Municipal Hospital signed a 10-year contract for a new diagnostics and analysis center at the hospital. As general contractor, Siemens Healthineers will supply all the medical technology for a the new, highly automated interdisciplinary center and operate it across manufacturers.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the completion of a comprehensive hospital-wide analysis of Tampere Heart Hospital - Tampere University Hospital's (Finland) environmental sustainability, including a deep assessment of the interventional cardiology space and evaluation of its carbon footprint.

Bayer and Hologic, Inc., today announced an international partnership to deliver contrast-enhanced-mammography (CEM) solutions to improve the detection of breast cancer in multiple countries across Canada, the European and Asia Pacific regions.

CEM is an innovative highly sensitive and low-cost breast imaging modality which combines digital mammography with the administration of a contrast agent to support breast cancer diagnosis and guide treatment decisions.